三生国健: 三生国健药业（上海）股份有限公司章程（2025年8月修订）

General Provisions - The company is established as a joint-stock limited company in accordance with the Company Law and other relevant regulations [1] - The company was registered on June 23, 2020, and issued 61,621,142 shares of ordinary stock to the public, which were listed on the Shanghai Stock Exchange on July 22, 2020 [1][3] - The registered capital of the company is RMB 616,785,793 [2] Business Objectives and Scope - The company's business objective is to focus on patients, quality, and innovation, aiming to become a leader in the antibody drug field in China [3] - The business scope includes medical research and development, technical services, drug production, import and export, and medical device operations [4][5] Shares - The company's shares are issued in the form of stocks, with each share having a par value of RMB 1 [6][7] - The total share capital of the company is RMB 616,785,793, with a total of 616,785,793 shares, all of which are ordinary shares [7][8] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, supervision of company operations, and access to company documents [12][13] - Shareholders must comply with laws and the company's articles of association, and they cannot withdraw their capital except as legally permitted [15] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with specific procedures for calling and conducting these meetings [21][22] - Shareholder meetings require a quorum and must follow legal and procedural requirements for decision-making [36][37] Financial Assistance and Guarantees - The company may provide financial assistance for acquiring its shares under certain conditions, but the total amount cannot exceed 10% of the issued share capital [8] - Any external guarantees provided by the company must be approved by the shareholders if they exceed specified thresholds [46][47]